The Lancet Infectious Diseases· Katrina M Pollock, Jack E Saunders, Jamie Fowler, Susana Camara, Ilona Kakai, Agnes Eordogh, Gareth Plested, Catherine M Green, Carla Ferreira da Silva, Philip de Whalley, Mohammod K Islam, Natalie G Marchevsky, Sandra Belij-Rammerstorfer, Teresa Lambe, CCHF01 Study Team·· 4 小时前AI 评分35
英国克里米亚–刚果出血热腺病毒载体疫苗的安全性与免疫原性（CCHF01）：一项开放标签、首次人体、非随机 I 期临床试验
[Articles] Safety and immunogenicity of an adenoviral-vectored vaccine against Crimean–Congo haemorrhagic fever in the UK (CCHF01): an open-label, first-in-human, non-randomised, phase 1 clinical trial
AI 导读
ChAdOx2 CCHF在I期临床试验中显示出可接受的耐受性，并诱导了CCHFV特异性体液免疫应答。这些结果为针对CCHFV的疫苗接种提供了概念验证，支持进一步临床开发。受样本量及组间年龄差异限制，既往接种ChAdOx载体疫苗对免疫原性的影响尚无法明确。
来源：The Lancet Infectious Diseases · thelancet.com